Methods for diagnosing and treating cancers
AssigneeResearch Development Foundation
InventorsTyler J. CURIEL, Anand Kornepati
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for the diagnosis, assessment, and treatment of cancer. In some aspects, detection of intracellular or cytoplasmic PD-L1, or measuring the ratio of cytoplasmic to surface PD-L1, can be used to identify cancers that may respond to immunotherapies or a DDR inhibitor such as, e.g., a Chk1 inhibitor, a PARP inhibitor, an ATM inhibitor, or an ATR inhibitor.
Claims55
A method of treating a cancer in a mammalian subject, comprising measuring expression of
- i) cytoplasmic PD-L1 and/or
- ii) one or more Lamtor proteins in the cancer;
- wherein if the expression of cytoplasmic or intracellular PD-L1 or one or more LAMTOR proteins is decreased relative to a normal control, then the method comprises administering an anti-cancer therapy to the subject.
47-48. (canceled)
(canceled)
A method for identifying an anti-cancer compound, comprising:
- i) contacting a cancerous cell with a test compound;
- and subsequently
- ii) measuring the level of expression in the cancerous cell of:
- (a) cytoplasmic PD-L1 and/or
- (b) one or more LAMTOR proteins;
- wherein the cancerous cell expresses cytoplasmic or intracellular PD-L1 and/or one or more LAMTOR proteins;
- and wherein a decrease in cytoplasmic or intracellular PD-L1 or one or more LAMTOR proteins in the cancerous cell indicates that the test compound has anti-cancer properties.
52-54. (canceled)
An in vitro method for diagnosing a cancer, comprising:
- i) obtaining a tissue sample comprising a cancer;
- and
- ii) measuring the level of expression in the cancer of
- (a) cytoplasmic or intracellular PD-L1 and/or
- (b) one or more LAMTOR proteins;
- wherein if the expression of cytoplasmic or intracellular PD-L1 or one or more LAMTOR proteins is decreased relative to a normal control, then the method comprises administering an anti-cancer therapy to the subject.
56-89. (canceled)
A method of treating a cancer in a mammalian subject, comprising administering to the subject a therapeutically relevant dose of:
- (i) 9-(2-phosphonylmethoxyethyl)guanine (PMEG), chlorambucil, or a beta-lactam antibiotic, and
- (ii) an antibody that selectively binds PD-L1 or PD-1
- to the mammalian subject, and wherein the cancer is melanoma, ovarian cancer, gastric cancer, hepatocellular carcinoma, renal cell carcinoma, esophageal cancer, pancreatic cancer, ovarian cancer, bladder cancer, lung cancer, colorectal cancer, melanoma, breast cancer, cervical cancer, hepatocellular cancer, head and neck cancer, sarcoma, lymphoma, leukemia, urothelial cancer, or myelodysplasia or sarcoma.
91-103. (canceled)
Dependencies are inferred from the claim text.